Monitoring Agency Report for the Quarter-II of F.Y. 2025-26, ended on September 30, 2025- Qrchid Pharma Limited
ORCHPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Orchid Pharma Limited has submitted its Monitoring Agency Report for the second quarter of FY 2025-26, covering the period ended September 30, 2025, to the stock exchanges. Monitoring Agency Reports are typically filed by companies that have raised capital through preferential allotments, rights issues, or QIPs, where a designated agency monitors the end-use of the proceeds. These reports are a routine regulatory compliance under SEBI regulations, usually required when the issue size exceeds ₹100 crore. The headline does not flag any deviations, suggesting that the funds raised are being deployed in line with the originally stated objectives.
This is a routine compliance filing and is largely neutral for shareholders. Investors should review the detailed report for any flags on fund utilization, though absence of any highlighted concern typically indicates proceeds are being used as planned.